Lymph Node Progression and Optimized Node Dissection of Middle Thoracic Esophageal Squamous Cell Carcinoma in the Latest Therapeutic Surgical Strategy

  • Takafumi Soeno
  • Hiroki Harada
  • Kei Hosoda
  • Hiroaki Mieno
  • Akira Ema
  • Hideki Ushiku
  • Marie Washio
  • Yoshimasa Kosaka
  • Masahiko Watanabe
  • Keishi YamashitaEmail author
Thoracic Oncology



The aim of this study is to elucidate the optimized lymph node dissection range in middle thoracic (Mt) esophageal squamous cell carcinoma (ESCC) requiring surgery.

Patients and Methods

We retrospectively analyzed 165 ESCC patients who underwent surgery with curative intent between 2009 and 2016, including 99 (60%) with MtESCC. Preoperative chemotherapy was administered in more than 80% of cStage II/III MtESCC patients. The rates of pathological and potential metastasis (representing recurrences) to lymph nodes and prognosis (median follow-up 52 months) were clarified. Lymph node dissection efficacy was assessed by calculating the efficacy index (EI) for each lymph node.


No. 2R had the highest rate of metastasis, with frequencies of 13/38/46% in cStage I/II/III, respectively, with the highest EI in MtESCC. Recurrences were seen in about 2–10% in the regional (nos. 1, 2L, 4R, and 10) and extraregional lymph nodes (paraaortic lymph node). The EI of lymph nodes was found to exhibit the highest score of 15 for no. 2R, followed by 11.5 for no. 17. The 5-year overall survival (OS) in MtESCC patients who underwent no. 2R lymph node dissection was 73.8%, while those who did not undergo no. 2R dissection did never reach 5-year OS (P = 0.002).


Meticulous lymph node dissection of no. 2R is the most important for long-term survival, and mandatory with the highest priority in MtESCC.



The authors have no conflicts of interest to declare.

Supplementary material

10434_2019_7190_MOESM1_ESM.tif (85 kb)
Supplementary material 1 (TIFF 85 kb)
10434_2019_7190_MOESM2_ESM.tif (97 kb)
Supplementary material 2 (TIFF 96 kb)
10434_2019_7190_MOESM3_ESM.xlsx (14 kb)
Supplementary material 3 (XLSX 13 kb)


  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–86, 2015CrossRefGoogle Scholar
  2. 2.
    Wu SG, Dai MM, He ZY, et al. Patterns of regional lymph node recurrence after radical surgery for thoracic esophageal squamous cell carcinoma. Ann Thorac Surg. 101:551–7, 2016CrossRefGoogle Scholar
  3. 3.
    Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive Registry of Esophageal Cancer in Japan, 2011. Esophagus. 15:127–152, 2018CrossRefGoogle Scholar
  4. 4.
    Kumakura Y, Yokobori T, Yoshida T, et al. Elucidation of the anatomical mechanism of nodal skip metastasis in superficial thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 25:1221–1228, 2018CrossRefGoogle Scholar
  5. 5.
    Liu J, Liu Q, Wang Y, et al. Nodal skip metastasis is associated with a relatively poor prognosis in thoracic esophageal squamous cell carcinoma. Eur J Surg Oncol. 42:1202–5, 2016CrossRefGoogle Scholar
  6. 6.
    Wang F, Zheng Y, Wang Z, et al. Nodal skip metastasis in esophageal squamous cell carcinoma patients undergoing three-field lymphadenectomy. Ann Thorac Surg. 104:1187–1193, 2017CrossRefGoogle Scholar
  7. 7.
    Feng JF, Zhao Q, Chen QX. Prognostic value of subcarinal lymph node metastasis in patients with esophageal squamous cell carcinoma. Asian Pac J Cancer Prev. 14:3183–6, 2013CrossRefGoogle Scholar
  8. 8.
    Niwa Y, Koike M, Hattori M, et al. The prognostic relevance of subcarinal lymph node dissection in esophageal squamous cell carcinoma. Ann Surg Oncol. 23:611–8, 2016CrossRefGoogle Scholar
  9. 9.
    Miyata H, Yamasaki M, Makino T, et al. Therapeutic value of lymph node dissection for esophageal squamous cell carcinoma after neoadjuvant chemotherapy. J Surg Oncol. 112:60–5, 2015CrossRefGoogle Scholar
  10. 10.
    Wang ZQ, Deng HY, Hu Y, et al. Prognostic value of right upper mediastinal lymphadenectomy in Sweet procedure for esophageal cancer. J Thorac Dis. 8:3625–3632, 2016CrossRefGoogle Scholar
  11. 11.
    Hsu PK, Huang CS, Hsieh CC, et al. Role of right upper mediastinal lymph node metastasis in patients with esophageal squamous cell carcinoma after tri-incisional esophagectomies. Surgery. 156:1269–77, 2014CrossRefGoogle Scholar
  12. 12.
    Yamashita K, Makino T, Yamasaki M, et al. Comparison of short-term outcomes between 2- and 3-field lymph node dissection for esophageal cancer. Dis Esophagus. 30:1–8, 2017CrossRefGoogle Scholar
  13. 13.
    Yamashita K, Katada N, Moriya H, et al. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis. Gen Thorac Cardiovasc Surg. 64:209–15, 2016CrossRefGoogle Scholar
  14. 14.
    Yamashita K, Hosoda K, Moriya H, et al. Prognostic advantage of docetaxel/cisplatin/5-fluorouracil neoadjuvant chemotherapy in clinical stage II/III esophageal squamous cell carcinoma due to excellent control of preoperative disease and postoperative lymph node recurrence. Oncology. 92:221–228, 2017CrossRefGoogle Scholar
  15. 15.
    Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 19:68–74, 2012CrossRefGoogle Scholar
  16. 16.
    Harada H, Hosoda K, Moriya H, et al. Optimized lymph node dissection range during progression of lower thoracic esophageal squamous cell carcinoma in the latest therapeutic surgical strategy: A retrospective analysis. Oncol Lett. 16:3281–89, 2018Google Scholar
  17. 17.
    Hosoda K, Yamashita K, Katada N, et al. Impact of lower mediastinal lymphadenectomy for the treatment of esophagogastric junction carcinoma. Anticancer Res. 35:445–56, 2015Google Scholar
  18. 18.
    Park SY, Kim DJ, Jung HS, et al. Relationship between the size of metastatic lymph nodes and positron emission tomographic/computer tomographic findings in patients with esophageal squamous cell carcinoma. World J Surg. 39:2948–54, 2015CrossRefGoogle Scholar
  19. 19.
    Yu S, Lin J, Chen C, et al. Recurrent laryngeal nerve lymph node dissection may not be suitable for all early stage esophageal squamous cell carcinoma patients: an 8-year experience. J Thorac Dis. 8:2803–12, 2016CrossRefGoogle Scholar
  20. 20.
    Mine S, Watanabe M, Imamura Y, et al. Clinical significance of the pre-therapeutic nodal size in patients undergoing neo-adjuvant treatment followed by esophagectomy for esophageal squamous cell carcinoma. World J Surg. 41:184–90, 2017CrossRefGoogle Scholar
  21. 21.
    Makino T, Yamasaki M, Miyata H, et al. Solitary lymph node recurrence of esophageal squamous cell carcinoma: surgical failure or systemic disease? Ann Surg Oncol. 23:2087–93, 2016CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Takafumi Soeno
    • 1
  • Hiroki Harada
    • 1
  • Kei Hosoda
    • 1
  • Hiroaki Mieno
    • 1
  • Akira Ema
    • 1
  • Hideki Ushiku
    • 1
  • Marie Washio
    • 1
  • Yoshimasa Kosaka
    • 1
    • 2
  • Masahiko Watanabe
    • 1
  • Keishi Yamashita
    • 1
    • 3
    Email author
  1. 1.Department of SurgeryKitasato University School of MedicineKanagawaJapan
  2. 2.Department of Breast and Endocrine SurgeryKitasato University School of MedicineKanagawaJapan
  3. 3.Division of Advanced Surgical Oncology, Department of Research and Development Center for New Medical FrontiersKitasato University School of MedicineKanagawaJapan

Personalised recommendations